Cell & Gene Therapy Market to Hit $26B

The explosive growth forecast is underpinned by a pipeline of over 2,200 therapies in development worldwide, with expectations for more than 60 new gene therapies to gain approval by 2030. This expansion moves beyond oncology into new indications, with investors showing significant interest in treatments for autoimmune, neurological, and muscular diseases. A primary bottleneck remains manufacturing, where complex, resource-intensive legacy processes drive high therapeutic costs. The industry is shifting from artisanal methods to industrialized platforms by adopting automated and closed manufacturing systems, which reduce manual steps, lower contamination risks, and improve reproducibility. This transition is critical for scaling both autologous and allogeneic therapies. Digital integration is central to modernizing bioprocessing, connecting robotics, sensors, and software analytics into a cohesive digital ecosystem. The implementation of Process Analytical Technology (PAT), Laboratory Information Management Systems (LIMS), and predictive analytics enables real-time process monitoring and control, forming the foundation for digital twins that can optimize viral vector yields and quality. AI and machine learning are being applied to de-risk development and streamline manufacturing operations. Applied AI models can optimize bioreactor seeding densities to increase productivity by up to 50%, while other algorithms are being used to design more effective and less immunogenic gene-editing proteins. Contract Development and Manufacturing Organizations (CDMOs) are critical in this landscape, providing the specialized infrastructure and regulatory expertise that many biotechs lack. The cell and gene therapy CDMO market is projected to see a compound annual growth rate of 17.5% between 2023 and 2029, reflecting the high demand for outsourced manufacturing capabilities. Despite the clinical promise, the investment climate has shifted, with venture capital funding for CGT companies dropping significantly since its peak in 2021. Investors have become more cautious, prioritizing clinically significant data and technologies that address key manufacturing and scalability challenges. Scientific advances continue to accelerate, focusing on moving from patient-specific autologous therapies to "off-the-shelf" allogeneic treatments. There is also a major push towards non-viral delivery systems, including lipid nanoparticles and CRISPR-based technologies, to bypass the complexities and costs associated with viral vector production.